Adding corticosteroid fluocortolone with standard therapy improves visual acuity in NAION patients
Nonarteritic anterior ischemic optic neuropathy is one of the leading causes of sudden and irreversible loss of vision in older adults. In a prospective randomized trial of 60 patients with NAION, investigators have shown that the addition of the corticosteroid fluocortolone to standard therapy significantly improves both short- and long-term visual acuity, especially when given soon after the onset of symptoms. Their results are published in Restorative Neurology and Neuroscience.